Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
ARV-393 by Arvinas for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval
ARV-393 is under clinical development by Arvinas and currently in Phase I for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy. According to...
Data Insights
ARV-393 by Arvinas for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
ARV-393 is under clinical development by Arvinas and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData,...